Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nortriptyline
Drug ID BADD_D01588
Description Nortriptyline hydrochloride, the active metabolite of [amitriptyline], is a tricyclic antidepressant (TCA).[L11878] It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.[L11881]
Indications and Usage Nortriptyline is indicated for the relief of the symptoms of major depressive disorder (MDD).[L11878] Some off-label uses for this drug include treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome.[A191083,L11878]
Marketing Status approved
ATC Code N06AA10
DrugBank ID DB00540
KEGG ID D08288
MeSH ID D009661
PubChem ID 4543
TTD Drug ID D04WFD
NDC Product Code Not Available
UNII BL03SY4LXB
Synonyms Nortriptyline | Desitriptyline | Desmethylamitriptylin | Allegron | Apo-Nortriptyline | Apo Nortriptyline | Aventyl | Gen-Nortriptyline | Gen Nortriptyline | Paxtibi | Nortrilen | Nortriptyline Hydrochloride | Hydrochloride, Nortriptyline | Novo-Nortriptyline | Novo Nortriptyline | Nu-Nortriptyline | Nu Nortriptyline | Pamelor | PMS-Nortriptyline | PMS Nortriptyline | ratio-Nortriptyline | ratio Nortriptyline | Norfenazin
Chemical Information
Molecular Formula C19H21N
CAS Registry Number 72-69-5
SMILES CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gynaecomastia21.05.04.003; 05.05.02.003--
Hallucination19.10.04.003--
Headache17.14.01.001--
Heart rate irregular13.14.04.003--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.004--Not Available
Hyperacusis17.04.03.003; 04.02.02.001--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.0030.000404%
Hypertension24.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypomania19.16.02.001--Not Available
Hypotension24.06.03.0020.000178%
Ileus paralytic07.02.05.001--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000261%
Leukopenia01.02.02.001--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Lymphadenitis01.09.01.001--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Menopausal symptoms21.02.02.002--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene